Skip to content
Insulet
-
Insulet establishes Riyadh Regional Headquarters to accelerate Omnipod 5 expansion in Middle East
The new office will host Insulet’s full regional leadership and operational teams, serving as the company’s central hub for clinical collaboration, partner development, market access initiatives, and talent investment across the region.
-
Insulet launches EVOLVE trial for fully closed-loop type 2 diabetes system
Insulet received Investigational Device Exemption approval from the U.S. Food and Drug Administration in March 2026, clearing the way for the trial to begin.